Kuria Entered into a Licensing Agreement with Scohia for SCO-116 to Treat Ophthalmic and Dermal Disease
Shots:
- Scohia to receive an up front & additional fees of ~$67M upon achievement of regulatory, development, & sales milestones along with royalties
- Kuria will be responsible for the global development, manufacturing & commercialization of SCO-116 (Nrf2 activator) for the prevention of eye & skin diseases with the guidance of JSE. Scohia obtains the global rights for SCO-116 for local delivery other than for eye, skin diseases & systemic formulation
- The safety & tolerability profile of SCO-116 has been shown in preliminary 1wk. toxicology studies in rats & monkeys. SCO-116 may be used to prevent or treat a wide range of conditions with unmet medical needs, including CKD, diabetic kidney disease, NASH, liver disease, eye & skin conditions
Ref: Bussinesswire | Image: Scohia Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
